Odyssey Therapeutics Inc. (ODTX)
NASDAQ: ODTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ODTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $815.23M
- EPS (TTM)
- -$6.33
- Dividend yield
- None
- 52-week range
- 15.10 – 29.05
- Day range
- 16.46 – 18.08
- Volume / Avg
- 677.84K / 329.31K
- Beta
- —
- Shares outstanding
- 48.07M
52-week range
ODTX stock today
Odyssey Therapeutics (ODTX) closed at $16.96 on Nov 20, down 7.52% (-$1.38), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 677.84K shares, a sign of unusually heavy trading. Shares are 41.6% below their 52-week high of $29.05, set on Sep 4, 2026 and 12.3% above the 52-week low of $15.10, near the bottom of the past year's range.
Odyssey Therapeutics has posted a net loss over the last twelve months (EPS of -$6.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Odyssey Therapeutics
Company profileOdyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Gary D. Glick Ph.D.
- Headquarters
- Boston, MA
- Employees
- 100
- IPO year
- 2026
- Website
- odysseytx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$34.67+104.42%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.10 vs $-1.13
- Surprise
- +2.65%
ODTX news
All ODTX news- Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Odyseey's OD-001 Shows Clinical Activity In Ulcerative Colitis, Advanced To Next Trial StageNasdaqODTX, LEN.B
- Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026GlobeNewswire
- Raymond James Initiates Coverage of Odyssey Therapeutics with OutperformNasdaq
Odyssey Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs ODTX |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs ODTX |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs ODTX |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs ODTX |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs ODTX |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs ODTX |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs ODTX |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs ODTX |
Indexes, lists and sector
Odyssey Therapeutics stock FAQ
What is Odyssey Therapeutics's stock price today?
ODTX last traded at $16.96 as of Nov 20, 4:00 PM EST, down 7.52% on the day. Prices are delayed at least 15 minutes.
Who is Odyssey Therapeutics's CEO?
Dr. Gary D. Glick Ph.D. is the chief executive officer of Odyssey Therapeutics Inc., which has about 100 employees.
What is the ODTX 52-week high?
The 52-week high for ODTX is $29.05 and the 52-week low is $15.10. The stock is currently 41.6% below its high.